WO2011140590A1 - Systèmes de liaison - Google Patents

Systèmes de liaison Download PDF

Info

Publication number
WO2011140590A1
WO2011140590A1 PCT/AU2011/000537 AU2011000537W WO2011140590A1 WO 2011140590 A1 WO2011140590 A1 WO 2011140590A1 AU 2011000537 W AU2011000537 W AU 2011000537W WO 2011140590 A1 WO2011140590 A1 WO 2011140590A1
Authority
WO
WIPO (PCT)
Prior art keywords
substrate
metal
oligomeric
metal ions
target molecule
Prior art date
Application number
PCT/AU2011/000537
Other languages
English (en)
Inventor
Nobuyoshi Joe Maeji
Liqun Yang
Nevin John Abernethy
Barbara Tengaten Fontanelle
Olya Aaliyah Savvina
Original Assignee
Bio-Layer Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio-Layer Pty Ltd filed Critical Bio-Layer Pty Ltd
Priority to AU2011252747A priority Critical patent/AU2011252747B2/en
Priority to US13/697,293 priority patent/US20130066077A1/en
Priority to JP2013509403A priority patent/JP5885266B2/ja
Priority to CN201180031172XA priority patent/CN102947340A/zh
Priority to EP11779968.4A priority patent/EP2569338A4/fr
Publication of WO2011140590A1 publication Critical patent/WO2011140590A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/14—Peptides being immobilised on, or in, an inorganic carrier

Definitions

  • the invention relates to the adaptation of synthetic surfaces for the immobilisation of target molecules thereon. Background of the invention
  • Immobilised metal ion affinity chromatography is a highly reliable purification procedure that has been applied to other applications such as protein refolding, biosensors, and plate based immunoassays (Ueda, E.K.M., Gout, P.W., and Morganti, L. J. Chromatography A, 988 (2003) 1-23).
  • IMAC Immobilised metal ion affinity chromatography
  • the metal ions are immobilised through metal chelating groups covalently attached to some solid support with some free coordination sites to which protein can bind through the poly-His tag. Subsequently, the bound protein can be released by competition with imidazole and other chelating agents.
  • poly-histidine tags need to be incorporated into proteins to eliminate problems of random metal-protein binding, unpredictable binding strength and reproducibility problems. Even so, metal interaction with poly-histidine tags is an intrinsically low affinity interaction and most proteins with only one poly-histidine tag would dissociate from a metal complex substrate under application conditions such as those found in solid phase assays.
  • the invention seeks to address at least one of the above mentioned problems or limitations, or to address at least one of the above mentioned needs, and in one embodiment provides a method of adapting a synthetic substrate for immobilisation of a target molecule thereon.
  • the method includes the following steps: - providing a synthetic substrate;
  • metal ions for binding with the substrate, wherein the metal ions are not complexed with a target molecule; - contacting the metal ions with the substrate in the absence of a target molecule thereby forming a co-ordination complex in which the substrate is bound to co-ordination sites of the metal ions;
  • oligomeric metal complexes from the metal ions in the presence of the substrate so that substantially all of the metal ions in the co-ordination complex with the substrate are in the form of oligomeric metal complexes; thereby adapting the substrate for immobilisation of a target molecule thereon.
  • a method of adapting a synthetic substrate for immobilisation of a target molecule thereon includes the following steps:
  • a method of adapting a synthetic substrate for immobilisation of a target molecule thereon including:
  • the two or more metal ions substantially in the form of an oligomeric metal complex may be screened/selected to provide a stable binding interaction or link between the target molecule and the substrate.
  • the target molecule is immobilised on the substrate through coordination with two or more metal ions substantially all in the form of oligomeric metal complexes. The mechanism that is believed to operate is explained in more detail below.
  • oligomeric metal complexes substantially all in the form of oligomeric metal complexes' is meant that the predominant proportion of the metal ions are in the form of oligomeric metal complexes (for example dimers, trimers, tetramers, etc), as opposed to monomelic metal complexes.
  • oligomeric metal complexes for example dimers, trimers, tetramers, etc
  • monomelic metal complexes preferably than 75%, preferably more than 80%, preferably more than 85%, preferably more than 90%, preferably more than 95%, preferably more than 98 or 99% of metal ions in the co-ordination complex with the substrate are in the form of oligomeric metal complexes.
  • the % amount of monomers or oligomers in a composition can be determined according to capillary electrophoresis methods described herein, and other methods known to the skilled worker.
  • a composition of metal ions wherein substantially all metal ions are in the form of oligomeric metal complexes can be obtained by fractionating a sample of metal complexes including monomelic and oligomeric complexes and recovering oligomeric complexes. It will be appreciated that in some embodiments, fractionation may be imperfect in which case there may be some residual monomelic metal complexes recovered with the oligomeric metal complexes.
  • the composition may be produced i conditions that favour the production of oligomeric metal complexes over monomeric metal complexes, in which case the composition includes metal ions, wherein substantially all metal ions are provided in the form of oligomeric metal complexes.
  • the composition contains metal ions in the form of both monomeric and oligomeric metal complexes which when applied to the substrate under specific conditions may allow the complexes to compete for the available chelation sites on the substrate such that monomeric metal complexes are in effect out-competed for the limited chelating sites on the substrate.
  • metal ions capable of binding with the substrate and the target molecule, the metal ions being in the form of oligomeric metal complexes and monomeric metal complexes;
  • the method employs a composition of oligomeric metal complexes, or substrate coated with same, the composition being characterised in that it does not substantially include monomeric metal complexes.
  • the oligomeric metal complexes may include more than one type of metal ion, or these complexes may consist of a single type of elemental metal ion.
  • the oligomeric metal complexes may include the same number of metal ions.
  • a composition of oligomeric metal complexes for use in conjugating or immobilising a target molecule on a substrate may include complexes having different numbers of metal ions.
  • a composition may have complexes that include 2, 3, 4, 5, 6, and more metal ions.
  • the oligomeric metal complexes may have the same conformation, geometry or structure.
  • a composition of metal ions for immobilising a target on a substrate may contain oligomeric metal complexes with differing conformations, geometries or structures. For example some may be linear, others branched, others clustered etc.
  • the present invention also resides in the synthesis and selection of oligomeric metal complexes (metal dimers, trimers, tetramers, etc) that have differential binding characteristics with respect to a target molecule and providing specific metal oligomers in such a manner that the binding outcome with respect to the target molecule can be further manipulated.
  • the oligomeric metal complexes may achieve higher binding affinity, and possibly varying levels of selectivity, with respect to the target molecule through improved binding effect of the oligomeric metal complex.
  • substrate is used generically to denote some species to which it is desired to bind a particular target molecule.
  • a “synthetic substrate” is generally a non biological substrate, i.e it is not a cell or cell fragment.
  • the “substrate” may be a conventional solid phase material that is a suitable platform for immobilising the target molecule of interest.
  • the substrate used will be a synthetic substrate of a format commonly used in pre-existing solid phase applications.
  • the substrate may include silica/glass, gold and other metals, or various plastic/polymer materials examples including poly(vinyIalcohol) surface or methacrylate surfaces.
  • the substrate may take any form.
  • the substrate will usually be in the form of micron or nanometer sized beads, membranes, multi-well plates, slides, capillary columns, cartridges or other formats.
  • the surface of the substrate may already contain carboxylic acids, amides, amines, hydroxy!, aldehyde or other electron donating groups, or modified to present low levels of electron donating groups on its surface.
  • the surface characteristics of the substrate may not have optimal metal chelation ligands but through selection of specific oligomeric metal complexes or specific combinations thereof, it is possible to achieve efficacy or optimisation of the method described herein.
  • the term "substrate” is intended to embrace such things as detectable labels and other molecular species.
  • label is used in the conventional sense to mean any species that is detectable and that may therefore be used to identify another molecule when attached thereto. The exact form of the label is not especially critical provided that the underlying principles of the present invention are applied.
  • the label may be a radioactive label, an enzyme, a specific binding pair component (e.g. avidin, streptavidin), a colorimetric marker or dye (e.g. UV, VIS or infra red dye), a fluorescent marker, chemiluminescent marker, an antibody, protein A, protein G, etc.
  • the present invention may have particular utility in the field of diagnostic assays and in principle any label conventionally used to provide increased signal detection in that context may be employed.
  • the term is intended to denote the active (detectable) label species per se or an active label species bound to a coordination ligand that enables the active label to be bound to the metal complex used in accordance with the present invention.
  • it may be necessary to screen and select specific oligomeric metal complexes or specific combinations thereof, to achieve the requisite association of active label species and metal of the metal complex.
  • the label may bind one or more oligomeric metal complexes and the oligomeric metal complex may bind one or more labels.
  • the label may be polymeric in character comprising multiple active label species and it has the ability to bind (chelate) more than one molecule of oligomeric metal complex.
  • label also embraces (pre-label) molecules, such as inorganic, organic or biomolecules (e.g. synthetic peptide Or oligonucleotides) that do not have the capability to function as an active label as such but that may be further reacted or functionalised to result in detection of the pre-labelled target molecule. In this case this further reactiori/functionalisation takes place without disruption of the binding (coordinate) interactions originally responsible for binding of the pre-label molecule and target molecule to the metal ion of the oligomeric metal complex. It will be appreciated that here the function of the metal complex is to act as a cross- linking agent between the target molecule and the pre-label molecule. As explained aboVe ⁇ the pre-label molecule may need to be bound to a suitable coordinate ligand in order to effect binding through the metal complex.
  • pre-label such as inorganic, organic or biomolecules (e.g. synthetic peptide Or oligonucleotides) that do not have the capability to function as an active
  • label and variations thereof, such as “labelling” will be used to embrace the embodiment described where the label is a pre-label and the effect of the invention is to facilitate cross- linking of the target molecule to the pre-label.
  • target molecule refers to any molecule that it is desired to label.
  • target molecule refers to a molecule that it is desired to immobilise on the substrate.
  • the target molecule is a biological molecule.
  • the invention has particular applicability in relation to antibodies as the target molecule.
  • target molecule may embrace any molecule that it is desired to immobilise on a substrate surface.
  • the target molecule may be a protein, such as an antibody, streptavidin, Protein A or Protein G.
  • oligomeric metal complex refers to a metal complex species comprising two or more monomelic species joined together.
  • the monomelic metal complex is the metal species formed when a metal ion in solution forms coordinate covalent bonds (also called dative covalent bonds) with electron donor ligands also present in solution.
  • coordinate covalent bonds also called dative covalent bonds
  • ligands will be called herein coordination ligands, metal ligands or simply, ligands.
  • chromium (III) may exist as an octahedral complex with six coordinate water molecules arranged around a central chromium ion.
  • the nature of the monomelic metal complex formed for any given metal will depend upon the ligands in solution as well as the ability of the ligands to form. suitably stable associations with the metal ion.
  • the ligands may be mono-, bi- or poly-dentate depending upon their structure and ability to interact with the metal ion thereby forming a complex. Hydrates and/or anions are ligands (also called counter ions) that will invariably be part of the structure of the metal complex in solution.
  • the oligomeric metal complex comprises at least two of these monomelic metal complexes bound together, through one or more bridging interactions of a ligand.
  • oligomeric complexes can be formed by more ligands bridging more metal species to form clusters comprising many monomelic metal species.
  • the monomelic metal complexes may be bound together to form oligomeric metal complexes having any conformation, geometry or structure.
  • the oligomeric metal complexes may have a linear, branched or cluster geometry or conformation.
  • Figure 1 depicts three oligomeric complexes based on chromium. In this particular case, different pH conditions can result in bonding of individual monomeric chromium complexes, i.e.
  • the chromium based oligomeric metal complexes are hydrolytic oligomeric metal complexes.
  • chromium oligomeric metal complexes are formed through other bridging ligands between two or more individual metal ions.
  • different methods of bridging metal complex can be used in combination.
  • other metal complexes form oligomeric species, and different populations of oligomers are possible according to their specific method of formation.
  • oligomeric metal complexes As well, addition of other ligands or combinations of ligands may result in more complex oligomeric metal complexes according to their specific method of formation.
  • the structure of the oligomeric metal complexes is likely to impart different binding characteristics compared with the constituent monomeric form metal complexes as well as between the different oligomeric species.
  • oligomeric metal complexes have greater 3 -dimensional complexity this provides greater flexibility of design than monomeric metal complexes.
  • the present invention resides in selecting the most suitable oligomeric metal complex or mixtures thereof in order to achieve the desired binding interactions between target molecules and substrates that may not have appropriately strong chelation species for monomeric metal complexes. With this in mind the present invention is believed to have applicability to a range of different oligomeric metal complexes in terms of type of metal and oligomeric forms, and variation of these metal complexes represent a point of diversity that allows greater flexibility of practice of the present invention.
  • the mechanism, by which the metal complex facilitates binding of the target molecule, or rather a region of the target molecule, is believed to involve displacement by the target molecule of one or more ligands associated with the oligomeric metal complexes. For this to occur the target molecule must be able to form preferential associations with the metal ion of the metal complex when compared to one or more existing coordination ligands that are already present in association with the metal ion prior to interaction with the target molecule. It is possible in accordance with an embodiment of the invention to manipulate the binding characteristics of the metal ion with respect to the target molecule in order to achieve the desired binding interaction. Thus, in an embodiment of the invention one or more ligands associated with the metal ion are selected in order to control binding of the target molecule as required.
  • the oligomeric metal complexes may facilitate binding to the substrate by a similar ligand displacement mechanism as described above in connection with the target molecule, and the binding characteristics of the metal ion with respect to the substrate may also be manipulated as necessary.
  • the species formed when a metal ion binds a target molecule could be regarded as being a metal complex since when bound the target molecule is a coordination ligand associated with the metal ion. The same could be said for the species formed when a metal ion binds to a substrate.
  • metal complex will be used herein to refer to the oligomeric metal complex and associated coordinate ligands before any such binding events have taken place.
  • coordinate and bind, and coordination and binding interaction are used interchangeably.
  • oligomeric metal complexes imparts greater binding stability due to multiple binding interactions between the oligomeric metal complex and the substrate or target molecule.
  • the strength of the coordinate bonds are tunable from essentially nonreversible covalent bonds to weak binding interactions.
  • the method of the present invention is likely to have particular applicability in solid- phase assays where it is desired to immobilise one or more target molecules on a solid substrate or to label target molecules with some detectable "tag" for identification purposes (in so-called capture assays).
  • the invention may also have utility in affinity chromatography, 2D gel electrophoresis, surface plasmon resonance, both in vitro and in vivo imaging, delivery of therapeutic materials or processes and any other applications where a target molecule is known to be useful when bound to a substrate.
  • the invention extends to the application of the method in any of these practical contexts.
  • the term “comprise” and variations of the term, such as “comprising”, “comprises” and “comprised” are not intended to exclude further additives, components, integers or steps.
  • FIG. 1 The binding capacity of goat anti-mouse (GAM) polyclonal antibody to capture mouse monoclonal antibody-fluorescein changes depending on whether a monomelic or oiigomeric chromium ions were used to bind the substrate to the GAM antibody.
  • GAM goat anti-mouse
  • FIG. 3 Ademtech beads treated with lOOmM chromium perchlorate/ethylene diamine complexes at pH 3 having approx. 30% monomeric component shows aggregation/clumping with loss of Brownian motion.
  • Figure 4 Ademtech beads treated with lOmM chromium perchlorate/ethylene diamine complexes at pH 3 ' having approx. 30% monomeric component shows aggregation/clumping with loss of Brownian motion.
  • FIG. 7 Although aggregation and Brownian motion changes with different treatment of beads ( Figures 3 to 6), in this example, the binding capacity of goat anti-mouse (GAM) polyclonal antibody to capture mouse monoclonal antibody-HRP is similar.
  • GAM goat anti-mouse
  • Figure 8 The binding capacity of goat anti-mouse (GAM) polyclonal antibody to capture mouse monoclonal antibody-fluorescein changes with the different chromium oligomeric mixtures (designated Type X, Y and Z, respectively) used to bind the substrate to GAM antibody.
  • GAM goat anti-mouse
  • Figure 9 The binding capacity of mouse monoclonal antibody to capture goat anti- mouse (GAM) polyclonal antibody-fluorescein changes with the different chromium oligomeric mixtures (designated Type X, Y and Z, respectively) used to bind the substrate to Mouse antibody.
  • GAM goat anti- mouse
  • Figure 10 The use of different ligands at the same molar concentration to form different oligomeric complexes changes the binding capacity of goat anti-mouse (GAM) polyclonal antibody to capture mouse monoclonal antibody-fluorescein.
  • GAM goat anti-mouse
  • Oligomeric metal complexes are effective in binding antibodies on silica surfaces whether the surface has either -OH or -COOH functionalities.
  • the example shows comparable performance with polymeric beads using one particular formulation of oligomeric metal complexes, Figure 13.
  • binding streptavidin show that its capacity to capture biotinylated molecules is 2x superior with the Silica-COOH surface.
  • FIG. 14 Different coupling buffers used to couple oligomeric metal bead complexes changes the binding capacity of goat anti-mouse (GAM) polyclonal antibody to capture mouse monoclonal antibody-fluorescein.
  • GAM goat anti-mouse
  • Activated chromium oligomer bead complexes are stable showing the same performance when goat anti-mouse (GAM) antibody was coupled immediately or after 180 day storage. Even storage in PBS which is supposed to destroy binding gives better performance of GAM to capture mouse monoclonal antibody-fluorescein.
  • GAM goat anti-mouse
  • compositions and substrates prepared according to the methods of PCT/AU2005/00966 tend to have a lower content of oligomeric metal complexes (about 70% or less) and a higher content of .monomelic metal complexes (up to about 30%).
  • the compositions and substrates disclosed herein have an oligomeric metal complex content greater than 70% and higher than 90% and a monomelic metal complex content of as little as 10% or less.
  • the inventor has shown that the key advantages of modified binding of target molecule and improved increased robustness, reproducibility, and stability of activated substrate (i.e. substrate that by the process of the method is adapted for binding target) can arise from the higher content of oligomerie metal complexes. This was unanticipated at the time of the invention.
  • the invention is a method of adapting a synthetic substrate for immobilisation of a target molecule thereon.
  • the method includes the following steps: - providing a synthetic substrate;
  • This embodiment generally relates to forming a coating or layer of metal complexes on the surface of a substrate, the coating or layer being characterised in that substantially all metal complexes in the coating or layer are provided in the form of oligomerie complexes.
  • the product of this process may be referred to as an "activated substrate" in the sense that the substrate, in having oligomerie metal complexes arranged thereon is then able to bind to a target molecule for immobilisation of the target molecule thereon.
  • the inventor has found that generally the oligomerie metal complexes can be formed by providing conditions for forming electron donating groups for bridging or otherwise linking or bonding two or more metal ions.
  • the relatively higher pH ranges implemented form electron donating groups, for example on the substrate and also in a bridging ligand (described further below) that might be present with the metal ions, thereby assisting in oligomerisation and formation of the coordination complex between the substrate and oligomeric metal complexes.
  • the step of forming oligomeric metal complexes from the metal ions in the presence of the substrate so that substantially all of the metal ions in the co-ordination complex with the substrate are in the form of oligomeric metal complexes may be conducted in the absence of target molecule.
  • mat me metal ions can be made to form oligomeric metal complexes before contact with the substrate.
  • a composition is formed in which substantially all metal ions in the compositions are provided in the form of oligomeric metal complexes for contact with a substrate.
  • the step of forming oligomeric metal complexes from the metal ions in the absence of the substrate so that substantially all of the metal ions are in the form of oligomeric metal complexes may be conducted in the absence of target molecule.
  • oligomers are preferentially formed from monomelic metal complexes by providing conditions for forming electron donating groups for bridging or linking two or more metal ions in the composition. This can be done by providing a pH of 3.3 to about 11, preferably about 4 to 10, preferably about 4 to 8 or 4, 5, 6 or 7 to the composition.
  • the relevant pH conditions can be provided by providing a salt, or bridging ligands.
  • a “salt” is generally a compound which results from the replacement of one or more hydrogen atoms of an acid by metal atoms or electropositive radicals.
  • examples of salts include NaOH, KOH or NH4OH and other alkaline salts.
  • those preferred salts are those that will raise the pH of the metal complex/substrate composition, and particularly those that provide a counter ion capable of serving as a co-ordination ligand in the relevant co-ordination complex with substrate.
  • these may be in the form of a compound, generally an organic compound, that contains one or more functional groups with electron donating potential, particularly at the pH - ranges described above.
  • These ligands may be described as "basic” or “acidic” ligands. The latter are in depronated form in the above described pH ranges. Examples of basic ligands are described herein and preferred ligands include those containing an amine or imine group, especially ethylenediamine.
  • the invention resides in forming and identifying oligomeric metal complexes and/or their mixtures that are capable of achieving a predetermined and desired binding interaction between a target substrate and a target molecule.
  • the oligomeric metal complex may be regarded as being a form of cross-linking agent that facilitates binding of the target molecule to the target substrate.
  • the intention is to achieve a stable binding interaction involving the oligomeric metal complex, the targeted substrate and the target molecule under the conditions at which these species are exposed to one another.
  • the binding interaction must also be stable under the conditions of practical application of the present invention, such as a diagnostic assay or the like.
  • the oligomeric metal complex useful in practice of the present invention is one that is capable of undergoing thermodynamically stable ligand displacement thereby forming a stable binding interaction (i.e. coordinate bond) with the substrate and with the target molecule under the conditions (such as pH, temperature, ionic strength, etc.) at which these species are exposed to each other and under the conditions associated with the practical application (e.g. an assay) in which the methodology of the invention is employed.
  • This is achieved through multiple metal chelation within the oligomeric complex, that together in combination maintains the desired stability.
  • the substrate-metal, metal-target molecule and target substrate-metal-target molecule binding interaction(s) is/are thermodynamically stable due to a sufficient number of metal binding interactions such that the desired interactions prevail over other possible (coordination ligand) binding interactions that the metal may otherwise undergo depending upon the prevailing practical conditions under which the binding interaction(s) occur.
  • the nature of the crizeraction(s) between the metal and the target substrate is such that the target molecule does not become disassociated from the target substrate-metal complex after binding thereto via the oligomeric metal complex and/or their mixtures.
  • the oligomeric complex useful in the invention is one that forms a sufficiently strong interaction with target molecule but can be subsequently detached from the oligomeric complex on the substrate.
  • the oligomeric metal complexes include one or more binding ligands selected to determine the overall molecular weight distribution and size range of the final oligomeric metal complex, and hence changing the overall binding characteristics of the metal complex for the substrate and/or target molecule.
  • the oligomeric metal complex and target substrate are bound to each other prior to exposure to the target molecule.
  • the addition of target molecule could be done immediately after formation of the oligomeric metal - substrate complex, or alternatively, be performed on oligomeric metal - substrate complexes stored for some period of time.
  • the method of the invention involves forming an oligomeric metal-substrate complex that is both storable and active to bind target molecule on exposing a predetermined metal-target substrate complex to an analyte containing the target molecule.
  • Selection of a suitable oligomeric metal complex(es) to form the metal-target substrate complex will depend upon a variety of factors. The mechanism by which the metal- target substrate complex binds to the target molecule, or rather to a region of the target molecule, is believed to involve displacement by the target molecule of one or more ligands associated with the oligomeric metal complex.
  • the target molecule must be able to form preferential associations with the metal ions of the metal -target substrate complex when compared to one or more existing coordinate ligands that are already in association with the metal complex prior to interaction with the target molecule. It is possible in accordance with an embodiment of the invention to manipulate the binding characteristics of the metal-target substrate complex with respect to both long term storage and to the target molecule in order to achieve the desired binding interaction with the target molecule.
  • metal ions examples include ions of transition metals such as scandium, titanium, vanadium, chromium, ruthenium, platinum, manganese, iron, cobalt, nickel, copper, molybdenum and zinc. Chromium, ruthenium, iron, cobalt, aluminium and rhodium are preferred.
  • metals in accordance with the invention may vary depending on the oxidation state of the metal.
  • chromium (III) may be useful in embodiments of the : invention.
  • One or more binding ligands may be included in the oligomeric metal complex to determine the overall molecular weight distribution and size range of the final oligomeric metal complex.
  • Ligands containing electron donating species can be used to form oligomeric metal complexes. Simple ions such as OH " or NH " , to more complicated structures can be used as bridging ligands. Both basic and acidic ligands can be used.
  • Ligands containing one or more lone pairs of electrons can be amines, imines, carbonyls, ethers, esters, oximes, alcohols, thioethers amongst others.
  • Other examples of basic ligands include pyridine, imidazole, benzimidazoe, histidine, or pyridine, most preferably ethylene diamine.
  • Acidic ligand that can coordinate with metal complexes on losing a proton can be carboxylic acids, sulphonic acids, phosphoric acids, enolic, phenolic, thioenolic or thiophenolic groups, amongst others.
  • acidic ligands include iminodiacetic acid, nitrilotracetic acid, oxalic acid, or salicylic acid.
  • bridging ligands can also be used.
  • amine ligands may be selected from the group including, but not limited to, ammonia, ethylamine, ethylenediamine, diethylenetriamine, bis-aminopropylethylene diamine, etc. In such cases, both OH " or NH 2 - can act as bridging ligands.
  • Such oligomeric metal complexes can be further manipulated by addition of other bridging ligands such as those containing carboxylic acids to form more complex structures. Any ligand able to bridge across 2 or more metal ions can be used to form oligomeric metal complexes and as a consequence, binding of the oligomeric metal complex to bind target substrate and/or target molecule is further affected.
  • the oligomeric metal complex may bind to the target substrate by mono-, bi- or poly- dentate ligands that already exist on the target substrate. Any electron donating groups can bind with oligomeric metal complexes. Both basic or acidic ligands can be used. Ligands containing one or more lone pairs of electrons can be amines, imines, carbonyls, ethers, esters, oximes, alcohols, thioethers amongst others. Acidic ligand that can coordinate with metal complexes on losing a proton can be carboxylic acids, sulphonic acids, phosphoric acids, enolic and phenolic groups, amongst others.
  • the concentration of the metal ions for oligomerisation in the methods of the invention may be selected so that the product of the relevant method is non aggregated substrate, for example where the substrate is in the form of beads, non aggregated beads.
  • the counter ions included in me oligomeric metal complex may be selected from the group consisting of but not limited to chloride, acetate, bromide, phosphate, nitrate, perchlorate, alum and sulphate.
  • a monomeric metal ion complex bound to the substrate may be oligomerized (by suitable exposure thereto) to form an (oligomeric metal ion complex)-(target substrate) conjugate.
  • the substrate is then cross-linked by exposing this conjugate to the target molecule, the metal ion moiety of the conjugate undergoing a binding interaction with the target molecule as a result of displacement of one or more coordinate ligands (still) associated with the metal ion when bound to the substrate. Similar selection criteria for the metal complex as described above will apply.
  • the oligomeric metal ion complex is bound to the target molecule (by suitable exposure thereto) to form a (metal ion)-(target molecule) conjugate.
  • the target molecule is then cross-linked by exposing this conjugate to the substrate, the metal ion complex moiety of the conjugate undergoing a binding interaction witih the target substrate as a result of displacement of one or more coordinate ligands (still) associated with the metal ion complex when bound to the target molecule.
  • Similar selection criteria for the oligomeric metal complex as described above will apply.
  • the reaction mixture may also contain buffers and or preservatives, typically from the analyte to stabilise the target molecule.
  • buffers and or preservatives typically from the analyte to stabilise the target molecule.
  • any buffer or preservative, or rather ligands/ions from the buffer or preservative does not detrimentally interfere with binding interactions necessary to bind the target molecule to the substrate, by whatever order of binding events that occur.
  • the substrate and target molecule are able to interact with each other through the oligomeric metal complex in order to achieve the desired binding effect.
  • the oligomeric metal complex functions as a molecular "glue".
  • Preferential binding of the substrate and target molecule through the oligomeric a metal complex will be largely determined by thermodynamic considerations based on the prevailing conditions under which the target substrate and target molecule are exposed to each other in the presence of the oligomeric metal complex. In the context of an assay this will obviously be dependent upon the conditions under which the assay is performed and on the characteristics of the analyte containing the target molecule(s).
  • identification of suitable oligomeric metal complex(es), including the number and type to be used in the present invention may be undertaken through a process of discovery using a library of different combinations of species.
  • the ability of a particular metal compound to form a oligomeric metal complex, the conditions under which different oligomeric populations are formed and the. ability of the oligomeric metal complex to bind a particular substrate to a particular target molecule is assessed over a variety of different permutations based on the oligomeric metal compounds used, the substrate, the target molecule and the prevailing conditions.
  • the affinity for the substrate to a target molecule by interaction through oligomeric metal complexes may be assessed in order to identify combinations of variables that yield desirable results.
  • Examples include rhodium, platinum, scandium, aluminium, titanium, vanadium, chromium, ruthenium, manganese, iron, cobalt, nickel, copper, molybdenum or zinc. It has been found that certain metal compounds result in complexes (in aqueous solution) that are generally useful as leads in the discovery process described.
  • oligomeric metals such as Fe(III), Co (III), Al(III), Cr(III) and Ru(IV) can exist in a distribution of smaller oligomeric species formed by ⁇ -hydroxo and ⁇ - ⁇ bridges between the metal centres to give dimeric, trimeric, tetrameric and higher order oligomers but oligomeric metals are not just restricted to these metal ions, nor is oligomeric formation restricted only to ⁇ - hydroxo and ⁇ - ⁇ bridges. Chromium oligomers have been found to be especially suitable for practice of the present invention.
  • oligomerics species can be formed through additions of other chelating ligands such as ammonia, ethylamine, ethylene diamine, etc; and/or acetic acids, . succinic acids, etc, and the actual conditions of oligomer formation changes the population distribution of the various forms.
  • chelating ligands such as ammonia, ethylamine, ethylene diamine, etc; and/or acetic acids, . succinic acids, etc
  • the possible diversity of oligomeric complexes are greatly expanded and through multiple binding interactions, substrates and target molecules having low electron-donating potential are now able to form stable interactions for the practical application of the invention.
  • the ability to form and use diverse populations of metal oligomers have not been applied to improve the performance of applications requiring the binding of target molecules to target substrates.
  • the nature of the ligands in forming oligomeric metal complexes helps determine make up the metal complex and "available" for displacement by a target molecule may also be controlled in order to manipulate binding as required. For example, where it is has been found that a given functional group or region of the target molecule exhibits a particular binding affinity to a particular metal complex or metal-label complex, it may be possible to enhance (or weaken) the binding affinity by inclusion in the complex of one or more ligands that are more easily displaced when interaction with the target molecule takes place. In this and similar ways it may be possible to provide selectivity to some functional group or region of a given target molecule by varying the type of coordinate ligands present in the complex being used to bind the target molecule.
  • the present invention also provides a composition for immobilising a target molecule on a substrate including:
  • metal ion haying co-ordination sites capable of binding with a substrate and a target molecule ⁇ wherein substantially all of the metal ions are in the . form of oligomeric metal complexes.
  • the present invention also provides a synthetic substrate for detection of an analyte in a sample, including:
  • metal ions having co-ordination sites bound to the substrate and the target molecule, wherein substantially all of the metal ions are provided in the form of oligomeric metal complexes.
  • the present invention also provides a method for determining whether a sample contains an analyte including,
  • the present invention also provides a kit for immobilising a target molecule on a substrate including:
  • metal ions having co-ordination sites capable of binding with a substrate and a target molecule, wherein substantially all of the metal ions are in. the form of oligomeric metal complexes.
  • Example 1 Binding of Substrates to Monomeric chromium complexes, or to Oligomeric chromium complexes.
  • Binding target molecule onto bead substrates using monomeric chromium ions was compared to one example of an oligomeric chromium complex containing 0% monomeric form.
  • Chromium Perchlorate with Bis(3-aminopropyl)diethylamine Chromium Perchlorate with Bis(3-aminopropyl)diethylamine.
  • chromium perchlorate hexahydrate (2.3 g) was dissolved into 25 mL of purified water and mixed thoroughly until all solid dissolves.
  • 545 ul of bis(3- aminopropyl)diethylamine solution was added to 25 mL of purified water. The solutions were combined and stirred for 2 days at room temperature.
  • ProMag carboxyl-terminated magnetic beads (Cat.No. PMC3N/9080) were supplied from Bangs, IN, USA. To prepare the beads, allow them to reach room temperature and vortex the beads for 30 sec, then sonicate for another 60 see. Dispense 2x 50 uL of bead concentrate into a 2x 1.7 mL microtube. Place tubes on a magnetic rack for 1 min and carefully remove and discard the supernatant from the bead pellet. To the bead pellet, add to each tube 50 uL of the respective chromium solutions. Leave for 1 hr at RT with rotation. c.
  • the antibody loading assay on magnetic beads was performed according to the procedure below. In brief, the materials and methods are as described.
  • Detection Antibody Mouse-IgG-FITC (2 mgs/ml, Jackson, USA)
  • Assay Buffer 10 mM PBS, pH 7.4 containing 1% BSA, 0.05% Tween 20
  • Microplate 96-well Millipore 0.42um filter plate (Millipore, USA)
  • Assay Protocols Dilute 2.5 ul of each bead sample in 45 ul of Assay Buffer. After vortexing for at least 30 sees, remove 40 ul of suspension and dilute again in 760 ul of Assay Buffer. Dilute mouse IgG- FITC detection antibodies in Assay Buffer to working concentration of 10 ug/ml. After vortexing diluted bead suspension for at least 30 sees, add 100 ul of antibody coated beads to the wells. Remove the beads solution from wells using filter vaccuum apparatus. After adding 50 ul of detection antibodies to the appropriate wells, incubate for 60 mins at room temperature on the plate shaker in the dark. Remove the detection antibody solution form wells using filter vacuum apparatus.
  • oligomeric chromium ions Comparison of the goat anti-mouse antibody bound to magnetic beads using monomelic chromium ions vs oligomeric chromium ions showed very different capacity to bind mouse antibody. Under the same conditions, the oligomeric formulation gave five (5) times the binding of mouse antibody (see Figure 2).
  • the amine additive may initiate oligomerisation by 2 possible modes of action. Specifically, there are 4 amino groups in Bis(3-aminopropyl)diethylamine complex that may allow potential bridging between metal ions. Further, the pH at 4.3 may allow formation of hydrolytic links between metal ions.
  • Chromium di-mer, tri-mer and other oligomers were fractionated according to procedures described in Spiccia, L., Marty, W. and Giovanoli, R. Hydrolytic Trimer of Chromium(IIl). Synthesis through Chromite Cleavage and Use in the Preparation of the "Active" Trimer Hydroxide, Inorganic Chemistry, 1988, 27, 2660-2666, and Stunzi, H. and Marty, W. Early Stages of the Hydrolysis of Chromium(IIl) in Aqueous Solution. 1. Characterization of a Tetrameric Species, Inorganic Chemistry, 1983, 22, 2145-2150.
  • TSH capture antibody 100 ug/mL of the TSH capture antibody (OEM Concepts antibody, clone # 057-11003) in 50 mM acetate buffer (pH5.0) was used.
  • Anti TSH monoclonal antibody (OEM Concepts antibody, clone # 057-11003) were coupled to Luminex xMAP Microspheres using the recommended Luminex procedures. The beads were allowed to reach room temperature, vortex for 20 sec, then sonicated for another 20 sec. The beads must be suspended as single mono-dispersed particles. If any aggregate beads are observed, repeat the vortexing and sonication until aggregates are not observed. Dispense 100 uL of bead concentrate into a 1.7 mL microtube. Centrifuge the beads solution at 14,000 rpm for 3 min after which remove the tube and gently flick it to dislodge beads on the side of the tube, then centrifuge for 5 more min. Carefully remove and discard the supernatant from the bead pellet. Repeat washing procedure with 0.1M sodium phosphate buffer, pH 6.3.
  • Antibody coupled beads Add 10 uL of concentrate to 590 uL of Assay Buffer
  • Detection Antibody Detection anti-TSH monoclonal antibody (Medix Biochemica antibody, clone # 5403) was biotinylated using EZ-Link-Sulfo-NHS-LC-Biotin (Pierce). Working solution was 20 ug/mL in 10 mM PBS containing 1%BSA TSH Standards were prepared in 10 mM PBS containing 1%BS A
  • Streptavidin-R-Phycoerythrin 20 ug mL in 10 mM PBS containing 1%BS A
  • Pre-wet the filter plate by placing 100 uL of Wash Buffer into each well and applying vacuum sufficient to gently empty the wells. Add 20 uL of TSH Standard to the appropriate microliter wells. Add Assay Buffer to zero (0 ulU/ml) wells. Add 10 uL of the diluted bead mixture to the appropriate microtiter wells. Shake the filer plate at room temperature at 500 rpm for 1 hr in the dark, then add 20 uL of the Anti-TSH Detection Antibody solution to the appropriate microtiter wells.
  • the outcome of the TSH assays is distinctly different when different chromium species are used to bind anti-TSH antibody to Luminex beads.
  • the poorer signal with monomelic chromium ions suggest either poor binding of antibody or that the oligomeric species bind to different sites on the antibody so changing its binding capacity for TSH antigen.
  • Example 3 Increasing oligomer formation: Combination of amine and hydroxide binding ligands.
  • a Formation of different chromium solutions. Chromium Oligomer Solution (containing 30% monomer). In brief, chromium perchlorate hexahydrate (2.3 g) was dissolved into 25 mL of purified water and mixed thoroughly until all solid dissolves. Similarly, 190 ul of ethylene diamine solution was added to 25 mL of purified water. The solutions were combined and stirred overnight at room temperature. By CE, this solution contains approx. 30% monomer and the pH stabilized at approx pH 3.0. Both 100 mM and 10 mM solutions were prepared by dilution with de-ionised water.
  • Chromium Oligomer Solution (containing 10% monomer). To the above solutions (20 ml) 1.5M sodium hydroxide solution was added drop wise such that it did not exceed pH 5 and stabilised at pH 4 after 12 hrs. By CE, this pH modified solution contains less than 10% monomer Both 100 mM and 10 mM solutions were prepared by dilution with de-ionised water. b. Addition of chromium solutions to magnetic beads (Ademtech).
  • Ademtech carboxyl-terminated magnetic beads (Cat.No. 0215) were supplied from Ademtech, Fra.. To prepare the beads, allow them to reach room temperature and vortex the beads for 30 sec to resuspend the beads. Remove 200ul of stock suspension (10 mg microspheres) to a 1.5-ml microcentrifuge tube. Place the tube onto a magnetic separator for at least 60 sec, and taking care not to disturb the microsphere pellet, remove and discard the Ademtech MasterBeads solution. Remove the tube from the magnetic separator and resuspend the microspheres in 1.0 ml of deionised water. Resuspend the microspheres by vortexing for 30 sec, and divide into 4 x 250 ul in individual tubes. Place the tubes onto a magnetic separator for at least 60 sec to allow complete separation of microspheres from the wash solution. Taking care not to disturb the microsphere pellet, remove and discard the wash solution.
  • the antibody loading assay on magnetic beads was performed according to the procedure below. In brief, the materials and methods are as described.
  • Antibody coupled beads Detection Antibody Mouse Anti-Rabbit IgG-HRP (0.8 mgs/ml, Jackson, USA)
  • Assay Buffer 10 mM PBS, pH 7.4 containing 1% BSA, 0.05% Tween 20
  • Microplate 96-well polypropylene white plate - U-shape (BioSciencej Germany)
  • the different oligomeric compositions give different characteristics to the substrate.
  • Both 10 and lOOmM chromium perchlorate/ethylenediamine complex at pH 3 resulted in bead aggregation with disappearance of Brownian motion (see Figure 3 and 4).
  • the lOOmM chromium percMorate/e&ylenediarriine complex at pH 4 also resulted in bead aggregation with disappearance of Brownian motion (see Figure 5).
  • the lOmM concentration at pH 4 (formulation containing approximately 10% monomer by CE) showed no observable aggregation and maintained full Brownian motion comparable to the un-modified beads (see Figure 6).
  • BcMag Carboxyl-Terminated Magnetic beads (Cat. No. FB-101) supplied from Bioclone, CA, USA. To prepare the beads, allow them to reach room temperature and vortex the beads for 30 sec, then sonicate for another 60 sec. The beads must be suspended as single mono-dispersed particles. If any aggregate beads are observed, repeat the vortexing and sonication until aggregates are not observed. Dispense 50 uL of bead concentrate into a 1.7 mL microtube. Place all tubes on a magnetic rack for 1 min and carefully remove and discard the supernatant from the bead pellet.
  • the antibody loading assay on magnetic beads was performed according to the procedure below. In brief, the materials and methods are as described.
  • Goat anti-mouse-IgG-R-Phycoerythrin 250 ug ml, Sigma, USA.
  • Microplate PP White, U Form (Greinerbio, USA)
  • the binding capacity of goat anti-mouse (GAM) polyclonal antibody to capture mouse monoclonal antibody-fluorescein changes with the different chromium oligomeric mixtures (designated Type X, Y and Z, respectively) used to bind the GAM antibody to the substrate.
  • Example 5 Increasing oligomer formation: Using different amine ligands. a. Formation of different chromium oligomers.
  • Chromium Perchlorate with Ethylenediamine In brief, chromium perchlorate hexahydrate (2.3 g) was dissolved into 25 mL of purified water and mixed thoroughly until all solid dissolves. Similarly, 190 ul of ethylene diamine solution was added to 25 mL of purified water. The solutions were combined and stirred overnight at room temperature. By CE, this solution contains 30% monomer Chromium Perchlorate with Bis(3-aminopropyl)diethylamine. The pH was 2.3. In brief, chromium perchlorate hexahydrate (2.3 g) was dissolved into 25 mL of purified water and mixed thoroughly until all solid dissolves.
  • Detection Antibody Mouse-IgG-FITC (2 mgs/ml, Jackson, USA) buffer pH5.2 with MES buffer pH7. Antibody binding to surface bound chromium oligomers can differ according to washing buffer pH selection as determined by loading assay. a. Chromium species selection.
  • M-270 carboxyl-terminated magnetic beads (Cat.No. 143.16D) were supplied from Dynal, IN, Norway. To prepare the beads, allow them to reach room temperature and vortex the beads for 30 sec, then sonicate for another 60 sec. Dispense 2 x 140 uL of bead concentrate into 2x 1.7 mL microtube. Place tubes on a magnetic rack for 1 min and carefully remove and discard the supernatant from the bead pellet To the bead pellet, add to 420 uL of the chromium perchlorate/ethylenediamine solution. Leave for 1 hr at RT with rotation.
  • the antibody loading assay on magnetic beads was performed according to the procedure as previously described in Example 5d. e. Example of Results.
  • post treatment of metal - substrate complexes by changing pH conditions after forming oligomeric metal - substrate complexes and prior to addition of target molecule in the form of GAM polyclonal antibody can be used to further modify oligomeric metal compositions and subsequently changes binding and performance of target molecule.
  • Example 7 Influence of different surfaces and materials on forming optimum metal oligomer - substrate complexes.
  • a formulation having approx 30% monomelic component was used as a model to show that the surface properties of the substrate can significantly change the properties of target molecule binding and its performance. a. Chromium species selection.
  • the chromium perchlorate with ethylenediamine complex having approx 30% monomeric component was used as a model.
  • the antibody loading assay on magnetic beads was performed according to the procedure as previously described in Example 5d.
  • f. Coupling of Streptavidin to different chromium ligated bead surfaces Take the chromium oligomer activated beads (250 ul) from the rotor and vortex suspension for 30 sees (see Example 6b). Place tubes (for magnetic beads) on a magnetic rack for 1 min or place tubes (for non-magnetic beads) in Micro-centrifuge for 3 minutes at 12,000 SPR, and carefully remove and discard the supernatant from the bead pellet. Add to each tube, 250 ul of 50mM MES buffer (pH 5.2). Repeat vortexing, removal of supernatant and MES addition two (2) more times.
  • Biotin-Phycoerythrin (Biotin-RPE) loading assay on the streptavidin coupled beads was performed according to the procedure below. In brief, the materials and methods are as described.
  • Assay Components Streptavidin coupled beads.
  • oligomeric metal complexes are effective in binding antibodies on silica surfaces whether the surface has either -OH or -COOH functionalities.
  • the example shows comparable performance with polymeric beads using one particular formulation of oligomeric metal complexes.
  • the same oligomeric metal - substrate complexes are also effective in binding streptavidin but the profile of performance improvement is both substrate and oligomeric metal complex dependent (see Figure 13).
  • Example 8 Manipulating hydrolytic oligomer formation of oligomeric metal - substrate complexes in combination with target molecule binding.
  • a formulation having approx 30% monomelic component to form a metal - substrate complex was used as a model to determine the influence of changing the electron donating conditions in the complexes
  • the influence of target molecule coupling conditions is exemplified by comparing pH and ionic strength differences.
  • * b Addition of chromium oligomers to magnetic beads (Dynal).
  • M-270 carboxyl-terminated magnetic beads (Cat.No. 143.16D) were supplied from Dynal, IN, Norway. To prepare the beads, allow them to reach room temperature and vortex the beads for 30 sec, then sonicate for another 60 sec. Dispense 2 x 170 uL of bead concentrate into 2x 1.7 mL microtube. Place tubes on a magnetic rack for 1 min and carefully remove and discard the supernatant from the bead pellet; To the bead pellet, add to 510 uL of the respective chromium oligomer solutions. Leave for 1 hr at RT with rotation.
  • Example 9 Manipulating hydrolytic oligomer formation of oligomeric metal - substrate complexes. Forming a stable but active metal - substrate complexes.
  • a formulation having approx 30% monomelic component to form a metal - substrate complex was used as a model to determine the influence of changing the electron donating conditions in the complexes, and its subsequent effect on long term storage of oligomeric metal - substrate complexes depending on storage conditions.
  • the influence of different washing buffer was exemplified by comparison of dH20, MES buffer pH5.2 and MES buffer pH7.
  • Antibody binding to surface bound chromium oligomers can differ according to the storage conditions as determined by loading assay. a. Chromium species selection.
  • the chromium perchlorate with ethylenediamine complex having approx 30% monomeric component was used.
  • Silica carboxyl-terminated beads (Inv. L080722G) were supplied from Bangs, IN, USA. To prepare the beads, allow them to reach room temperature and vortex the beads for 30 sec, then sonicate for another 60 sec. Dispense 2 x 600 uL of bead concentrate into 2x 1.7 mL microtube. Place all tubes in Micro-centrifuge for 5 minutes at 2000 rpm and carefully remove and discard the supernatant from the bead pellet. To the bead pellet, add to 600 uL of chromium oligomer solution. Leave for 1 hr at RT with rotation. Split chromium oligomer activated Silica beads to three tubes.
  • Tube 1 the beads were washed with 200 uL of dH20 with 0.025% ProClin 300 and repeated two (2) more times.
  • the chromium oligomer activated Silica beads were store in 200 ul of dH20 with 0.025% ProClin 300.
  • Tube 2 the beads were washed with 200uL of 50mM MES pH5.2 with 0.025% ProClin 300 and repeated two (2) more times.
  • the chromium oligomer activated Silica beads store in 200 ul of 50mM MES pH5.2 with 0.025% ProClin 300.
  • Tube 3 the beads were washed with 200 uL of lOmM PBS pH7.4 with 0.025% ProClin 300 and repeated two (2) more times.
  • the chromium oligomer activated Silica beads store in 200 ul of lOmM PBS pH7.4 with 0.025% ProClin 300.
  • the antibody loading assay on magnetic beads was performed according to the procedure as previously described in Example 5d. ⁇ e. Example of Results.
  • activated chromium oligomer bead complexes are stable showing the same performance when goat anti-mouse (GAM) antibody was coupled immediately or after 180 day storage. Even storage in PBS which is supposed to destroy binding gives better performance of GAM to capture mouse monoclonal antibody-fluorescein.
  • GAM goat anti-mouse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention a pour objet un procédé d'adaptation d'un substrat synthétique pour l'immobilisation sur celui-ci d'une molécule cible.
PCT/AU2011/000537 2010-05-10 2011-05-10 Systèmes de liaison WO2011140590A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2011252747A AU2011252747B2 (en) 2010-05-10 2011-05-10 Binding systems
US13/697,293 US20130066077A1 (en) 2010-05-10 2011-05-10 Binding systems
JP2013509403A JP5885266B2 (ja) 2010-05-10 2011-05-10 結合系
CN201180031172XA CN102947340A (zh) 2010-05-10 2011-05-10 结合系统
EP11779968.4A EP2569338A4 (fr) 2010-05-10 2011-05-10 Systèmes de liaison

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33286610P 2010-05-10 2010-05-10
US61/332,866 2010-05-10

Publications (1)

Publication Number Publication Date
WO2011140590A1 true WO2011140590A1 (fr) 2011-11-17

Family

ID=44913756

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2011/000537 WO2011140590A1 (fr) 2010-05-10 2011-05-10 Systèmes de liaison

Country Status (6)

Country Link
US (1) US20130066077A1 (fr)
EP (1) EP2569338A4 (fr)
JP (1) JP5885266B2 (fr)
CN (1) CN102947340A (fr)
AU (1) AU2011252747B2 (fr)
WO (1) WO2011140590A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015021509A1 (fr) * 2013-08-13 2015-02-19 Anteo Technologies Pty Ltd Conjuguaison de molécules avec des particules
WO2015192183A1 (fr) 2014-06-17 2015-12-23 Anteo Technologies Pty Ltd Systèmes de liaison hétérofonctionnels
WO2017083938A1 (fr) 2015-11-20 2017-05-26 Anteo Technologies Pty Ltd Procédé d'échange compétitif contrôlé
WO2023056530A1 (fr) * 2021-10-08 2023-04-13 Anteo Technologies Pty Ltd Conjugaison de biomolécules

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023056529A1 (fr) * 2021-10-08 2023-04-13 Anteo Technologies Pty Ltd Support de liaison et ses utilisations
WO2023056528A1 (fr) * 2021-10-08 2023-04-13 Anteo Technologies Pty Ltd Dosage à écoulement latéral

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070178465A1 (en) * 2004-03-15 2007-08-02 Commissariat A L'energie Atomique N,n-dimethylacrylamide-based high molecular weight polymer
US20090209049A1 (en) * 2004-07-02 2009-08-20 Bio-Layer Pty Ltd Use of metal complexes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4624923A (en) * 1984-06-08 1986-11-25 Yeda Research And Development Company Limited Metal-coated polyaldehyde microspheres
EP0167834A3 (fr) * 1984-06-08 1988-03-09 Yeda Research And Development Company, Ltd. Microsphères en polyaldéhyde renfermant du métal
JPH05502944A (ja) * 1989-12-22 1993-05-20 モレキュラ　バイオクエスト　インコーポレイテッド 分離に使用するための有機金属で被覆された粒子
DE60231055D1 (de) * 2001-11-12 2009-03-19 Novo Nordisk As Reinigung von peptiden unter verwendung von metall-ion-affinitätschromatographie
WO2007076580A1 (fr) * 2005-12-30 2007-07-12 Bio-Layer Pty Limited Fixation de molécules

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070178465A1 (en) * 2004-03-15 2007-08-02 Commissariat A L'energie Atomique N,n-dimethylacrylamide-based high molecular weight polymer
US20090209049A1 (en) * 2004-07-02 2009-08-20 Bio-Layer Pty Ltd Use of metal complexes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2569338A4 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015021509A1 (fr) * 2013-08-13 2015-02-19 Anteo Technologies Pty Ltd Conjuguaison de molécules avec des particules
EP3033360A4 (fr) * 2013-08-13 2017-04-12 Anteo Technologies Pty Ltd. Conjuguaison de molécules avec des particules
AU2014306363B2 (en) * 2013-08-13 2019-05-02 Anteo Technologies Pty Ltd Conjugating molecules to particles
US11726095B2 (en) 2013-08-13 2023-08-15 Anteo Technologies Pty Ltd Conjugating molecules to particles
WO2015192183A1 (fr) 2014-06-17 2015-12-23 Anteo Technologies Pty Ltd Systèmes de liaison hétérofonctionnels
US10768176B2 (en) 2014-06-17 2020-09-08 Anteo Technologies Pty Ltd Hetero functional binding systems
WO2017083938A1 (fr) 2015-11-20 2017-05-26 Anteo Technologies Pty Ltd Procédé d'échange compétitif contrôlé
US11202835B2 (en) 2015-11-20 2021-12-21 Anteo Technologies Pty Ltd Method of controlled competitive exchange
AU2016358205B2 (en) * 2015-11-20 2022-01-06 Anteo Technologies Pty Ltd Method of controlled competitive exchange
WO2023056530A1 (fr) * 2021-10-08 2023-04-13 Anteo Technologies Pty Ltd Conjugaison de biomolécules

Also Published As

Publication number Publication date
AU2011252747B2 (en) 2016-05-19
CN102947340A (zh) 2013-02-27
AU2011252747A1 (en) 2012-12-06
EP2569338A1 (fr) 2013-03-20
EP2569338A4 (fr) 2014-01-08
JP5885266B2 (ja) 2016-03-15
US20130066077A1 (en) 2013-03-14
JP2013526701A (ja) 2013-06-24

Similar Documents

Publication Publication Date Title
AU2011252747B2 (en) Binding systems
EP2128616B1 (fr) Support ayant une protéine immobilisée sur celui-ci et son procédé de production
US9206225B2 (en) Materials and methods for isolating phosphopeptides
US20240053348A1 (en) Conjugating molecules to particles
US9777075B2 (en) Diagnostic assay using particles with magnetic properties
KR101826449B1 (ko) 펩티드 단편의 조제 방법 및 그것에 사용되는 펩티드 단편 조제용 킷, 및 분석 방법
Xiong et al. Ti 4+-immobilized multilayer polysaccharide coated magnetic nanoparticles for highly selective enrichment of phosphopeptides
Hao et al. A facile and general approach for preparation of glycoprotein-imprinted magnetic nanoparticles with synergistic selectivity
Deng et al. Guanidinium functionalized superparamagnetic silica spheres for selective enrichment of phosphopeptides and intact phosphoproteins from complex mixtures
AU2005259833B2 (en) Use of metal complexes
Zhang et al. Facile way to prepare a porous molecular imprinting lock for specifically recognizing oxytetracyclin based on coordination
Tang et al. An epitope imprinted polymer with affinity for kininogen fragments prepared by metal coordination interaction for cancer biomarker analysis
Hou et al. Selective recognition of a cyclic peptide hormone in human plasma by hydrazone bond-oriented surface imprinted nanoparticles
Ren et al. Isoform-specific recognition of phosphopeptides by molecular imprinting nanoparticles with double-binding mode
Roque et al. Antibody immobilization on magnetic particles
CN108028113A (zh) 不影响蛋白质功能性质的磁性纳米颗粒在交联蛋白质基质中的包埋
Peng et al. Magnetic quantitative analysis for multiplex glycoprotein with polymer-based elemental tags
Batalha et al. Mimicking nature: Phosphopeptide enrichment using combinatorial libraries of affinity ligands
Shu et al. Glycan-selective in-situ growth of thermoresponsive polymers for thermoprecipitation and enrichment of N-glycoprotein/glycopeptides
KR20170120697A (ko) 반응장을 제한한 프로테아제 분해 반응에 의한 항체로부터 펩티드 단편을 얻는 방법
JP5559465B2 (ja) アビジン類結合担体、その製造方法及びその使用方法
JPWO2006036003A1 (ja) 生体特異的親和性を有する物質を結合した微粒子及びその使用
WO2005010528A1 (fr) Procede d'elimination d'une substance non specifique
Kim et al. Rapid and sensitive detection of domoic acid in shellfish using a magnetic bead-based competitive ELISA with a high-affinity peptide as a molecular binder
Duong Novel customisable phases for micro solid-phase extraction and automated biological sample preparation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180031172.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11779968

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2013509403

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13697293

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 10601/DELNP/2012

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2011252747

Country of ref document: AU

Date of ref document: 20110510

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2011779968

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012028731

Country of ref document: BR

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112012028731

Country of ref document: BR

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: 112012028731

Country of ref document: BR